世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000028598

潰瘍性大腸炎:2029年までの薬剤予測および世界市場分析

GlobalData

Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029

発刊日 2020/12/31

言語英語

体裁PDF/168ページ

「PDF」版168ページ

0000028598

潰瘍性大腸炎:2029年までの薬剤予測および世界市場分析
Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029

10,995 USD

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

潰瘍性大腸炎(UC)は、炎症性腸疾患の一種です。潰瘍性大腸炎では、慢性的な炎症が大腸に影響を与えます。最初は、UCは通常、結腸の末端部分、直腸に症状が現れ、潰瘍性直腸炎と呼ばれています。大腸の左側全体に広がることもあれば、大腸全体に広がることもあります。現在の潰瘍性直腸炎市場は、軽度から中等度の疾患を対象とした安価なジェネリック医薬品、抗腫瘍壊死因子(TNF)や抗インテグリンなどの高価な生物学的製剤、重度の疾患を対象とした外科的治療の短期または長期代替品として使用されるバイオシミラー医薬品で過密状態にあります。この分野の研究開発は、5つの経口剤形、より便利な投与頻度、新規作用機序(MOA)、改善された安全性プロファイルを持つ10の後期パイプライン医薬品で構成されています。しかし、主要ブランドが予測期間中に特許失効となるため、バイオシミラーの出現が増加していることから、これらのパイプライン製品は課題となるでしょう。さらに、1剤を除いてすべてが中等度から重度のUC向けに開発されており、市場は混雑することになるでしょう。

本モデルでは、市販薬および後期パイプラインのUC治療薬の市場予測をカバーしています。このモデルでは、患者を重症度別に分類し、軽度・中等度、中等度・重度、重度・劇症の3つのセグメントに分類しています。本モデルの基準年は2019年、予測期間は2020~2029年です。

■調査範囲

  • 疫学、病因、病態、症状、治療ガイドラインなど、UCを概説します。
  • 市場収益、年間治療費、主要なパイプライン製品の売上予測を明らかにします。
  • 既存治療およびパイプライン治療、アンメットニーズと機会、UC治療薬の売上を促す/抑制する要因など、関連事項などを取り上げます。
  • パイプライン分析:さまざまな開発段階に渡る評価した包括的データ、開発中の新たな動向、開発後期候補化合物の概要を提供します。
  • 同市場における現在および将来の競合分析、市場の促進・抑制要因の分析を提供します。

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Ulcerative Colitis: Executive Summary
2.1 Large Growth is Expected for UC Market from 2019-2029
2.2 Competition and Biosimilar Threat Defines UC Market
2.3 Pipeline Products Partially Address Unmet Needs
2.4 Opportunities for Managing Severe/Fulminant Patients Remain
2.5 Subcutaneous Biologics and Oral Therapies to Drive Growth in UC Market
2.6 What Do Physicians and Payers Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for UC (2019-2029)
5.6 Discussion

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Treatment Overview
6.3 Treatment Guidelines and Leading Prescribed Drugs
6.4 US
6.5 5EU
6.6 Japan
6.7 Canada

7 Competitive Assessment
7.1 Overview
7.2 KOL and Payer Opinion on the Impact of COVID-19

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Safe and Efficacious Treatment Alternatives
8.3 Improved Medical Management for Severe/Fulminant Patients
8.4 Biomarkers to Predict Responsiveness to Therapy and Prognosis
8.5 Standardization of Patient-Reported Outcomes

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Johnson & Johnson
10.4 AbbVie
10.5 Takeda
10.6 Pfizer
10.7 Eli Lilly
10.8 EA Pharma
10.9 Galapagos
10.10 Bristol-Myers Squibb
10.11 Arena Pharmaceuticals

11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 Canada

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer

List of Tables
Table 1: UC: Key Metrics in the 8MM
Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters
Table 3: Montreal Classification for the Distribution of UC
Table 4: Typical Symptoms of UC
Table 5: Risk Factors and Comorbidities for UC and IBD
Table 6: Guidelines Used for Managing UC
Table 7: Country Profile - US
Table 8: Country Profile - 5EU
Table 9: Country Profile - Japan
Table 10: Country Profile - Canada
Table 11: Leading Treatments for UC, 2020
Table 12: Johnson & Johnson’s Disease Portfolio Assessment, 2020
Table 13: AbbVie’s Disease Portfolio Assessment, 2020
Table 14: Takeda’s Disease Portfolio Assessment, 2020
Table 15: Pfizer’s Disease Portfolio Assessment, 2020
Table 16: Eli Lilly’s Disease Portfolio Assessment, 2020
Table 17: EA Pharma’s Disease Portfolio Assessment, 2020
Table 18: Galapagos’ Disease Portfolio Assessment, 2020
Table 19: Bristol-Myers Squibb’s Disease Portfolio Assessment, 2019
Table 20: Arena’s Disease Portfolio Assessment, 2020
Table 21: Disease UC Market - Global Drivers and Barriers, 2019-2029
Table 22: Key Events Impacting Sales for Disease UC in the US, 2019-2029
Table 23: Disease UC Market - Drivers and Barriers in the US, 2019-2029
Table 24: Key Events Impacting Sales for Disease UC in the 5EU, 2019-2029
Table 25: Disease UC Market - Drivers and Barriers in the 5EU, 2019-2029
Table 26: Key Events Impacting Sales for Disease UC in Japan, 2019-2029
Table 27: Disease UC Market - Drivers and Barriers in Japan, 2019-2029
Table 28: Key Events Impacting Sales for Disease UC in Canada, 2019-2029
Table 29: UC Market -Drivers and Barriers in Canada, 2019-2029
Table 30: Key Historical and Projected Launch Dates for UC
Table 31: Key Historical and Projected Patent Expiry Dates for UC
Table 32: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Ulcerative Colitis in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in UC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC
Figure 5: Types of UC
Figure 6: 8MM, Diagnosed Incidence of UC, Men and Women, Cases per 100,000 Population, All Ages, 2019
Figure 7: 8MM, Diagnosed Prevalence of UC, Men and Women, %, All Ages, 2019
Figure 8: 8MM, Total Prevalence of UC, Men and Women, %, All Ages, 2019
Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of UC
Figure 10: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of UC
Figure 11: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of UC
Figure 12: 8MM, Sources Used to Forecast the Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC
Figure 13: 8MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of UC for Ages <18 years
Figure 14: 8MM, Diagnosed Incident Cases of UC, N, Both Sexes, All Ages, 2019
Figure 15: 8MM, Diagnosed Incident Cases of UC by Age, N, Both Sexes, 2019
Figure 16: 8MM, Diagnosed Incident Cases of UC by Sex, N, All Ages, 2019
Figure 17: 8MM, Diagnosed Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
Figure 18: 8MM, Diagnosed Prevalent Cases of UC by Age, N, Both Sexes, 2019
Figure 19: 8MM, Diagnosed Prevalent Cases of UC by Sex, N, All Ages, 2019
Figure 20: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages <18 years, 2019
Figure 21: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages ≥18 Years, 2019
Figure 22: 8MM, Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC, 2019
Figure 23: 8MM, Total Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
Figure 24: 8MM, Total Prevalent Cases of UC by Age, N, Both Sexes, 2019
Figure 25: 8MM, Total Prevalent Cases of UC by Sex, N, All Ages, 2019
Figure 26: UC Treatment Algorithm
Figure 27: Unmet Need and Opportunity in UC, 2020
Figure 28: Overview of the Development Pipeline in UC
Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for UC in the 8MM During the Forecast Period
Figure 30: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
Figure 31: Analysis of the Company Portfolio Gap in UC During the Forecast Period
Figure 32: Global (8MM) Sales Forecast by Country for UC in 2019 and 2029
Figure 33: Global (8MM) Sales Forecast by Class for UC in 2019 and 2029
Figure 34: Sales Forecast by Class for UC in the US in 2019 and 2029
Figure 35: Sales Forecast by Class for UC in the 5EU in 2019 and 2029
Figure 36: Sales Forecast by Class for UC in Japan in 2019 and 2029
Figure 37: Sales Forecast by Class for UC in Canada in 2019 and 2029

この商品のレポートナンバー

0000028598

TOP